Acknowledgement
This research was supported by grants from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) and a grant of Patient-Centered Clinical Research Coordinating Center (PACEN) funded by the Ministry of Health & Welfare, Republic of Korea (HC20C0081), the Korea Medical Device Development Fund funded by the Korean government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, the Ministry of Food and Drug Safety) (202011B29-03, 202011D12-02) and the Cardiovascular Research Center (Seoul, Korea).
References
- Ko YG, Ahn CM, Min PK, et al. Baseline characteristics of a retrospective patient cohort in the Korean Vascular Intervention Society Endovascular Therapy in Lower Limb Artery Diseases (K-VIS ELLA) Registry. Korean Circ J 2017;47:469-76.
- Poulson W, Kamenskiy A, Seas A, Deegan P, Lomneth C, MacTaggart J. Limb flexion-induced axial compression and bending in human femoropopliteal artery segments. J Vasc Surg 2018;67:607-13.
- Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017;135:e686-725.
- Kudagi VS, White CJ. Endovascular stents: a review of their use in peripheral arterial disease. Am J Cardiovasc Drugs 2013;13:199-212.
- Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 2015;131:495-502.
- Rosenfield K, Jaff MR, White CJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med 2015;373:145-53.
- Thieme M, Von Bilderling P, Paetzel C, et al. The 24-month results of the Lutonix Global SFA Registry: worldwide experience with Lutonix drug-coated balloon. JACC Cardiovasc Interv 2017;10:1682-90.
- Micari A, Brodmann M, Keirse K, et al. Drug-coated balloon treatment of femoropopliteal lesions for patients with intermittent claudication and ischemic rest pain: 2-year results from the IN.PACT global study. JACC Cardiovasc Interv 2018;11:945-53.
- Aboyans V, Ricco JB, Bartelink ME, et al. Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2018;55:305-68.
- Scheinert D, Micari A, Brodmann M, et al. Drug-coated balloon treatment for femoropopliteal artery disease. Circ Cardiovasc Interv 2018;11:e005654.
- Fanelli F, Cannavale A, Gazzetti M, et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol 2014;37:898-907.
- Katsanos K, Spiliopoulos S, Reppas L, Karnabatidis D. Debulking atherectomy in the peripheral arteries: is there a role and what is the evidence? Cardiovasc Intervent Radiol 2017;40:964-77.
- Lee YJ, Ko YG, Ahn CM, et al. Outcomes of adjunctive drug-coated versus uncoated balloon after atherectomy in femoropopliteal artery disease. Ann Vasc Surg 2020;68:391-9.
- Zeller T, Langhoff R, Rocha-Singh KJ, et al. Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: twelve-month results of the DEFINITIVE AR study. Circ Cardiovasc Interv 2017;10:e004848.
- Cai Z, Guo L, Qi L, et al. Midterm outcome of directional atherectomy combined with drug-coated balloon angioplasty versus drug-coated balloon angioplasty alone for femoropopliteal arteriosclerosis obliterans. Ann Vasc Surg 2020;64:181-7.
- Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv 2014;83:E212-20.
- Cioppa A, Stabile E, Popusoi G, et al. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: One-year single centre clinical results. Cardiovasc Revasc Med 2012;13:219-23.
- Zhen Y, Chang Z, Wang C, Liu Z, Zheng J. Directional atherectomy with antirestenotic therapy for femoropopliteal artery disease: a systematic review and meta-analysis. J Vasc Interv Radiol 2019;30:1586-92.
- Tarricone A, Ali Z, Rajamanickam A, et al. Histopathological evidence of adventitial or medial injury is a strong predictor of restenosis during directional atherectomy for peripheral artery disease. J Endovasc Ther 2015;22:712-5.
- Stavroulakis K, Schwindt A, Torsello G, et al. Directional atherectomy with antirestenotic therapy vs drug-coated balloon angioplasty alone for isolated popliteal artery lesions. J Endovasc Ther 2017;24:181-8.
- Stavroulakis K, Schwindt A, Torsello G, et al. Directional atherectomy with antirestenotic therapy vs drug-coated balloon angioplasty alone for common femoral artery atherosclerotic disease. J Endovasc Ther 2018;25:92-9.
- Krishnan P, Tarricone A, Purushothaman KR, et al. An algorithm for the use of embolic protection during atherectomy for femoral popliteal lesions. JACC Cardiovasc Interv 2017;10:403-10.
- Wasty N, Khakwani MZ, Kotev S, et al. Ubiquitous nature of distal athero/thromboembolic events during lower extremity atherectomy procedures involving the superficial femoral artery. Int J Angiol 2016;25:252-7.
- Boitet A, Grassin-Delyle S, Louedec L, et al. An experimental study of paclitaxel embolisation during drug coated balloon angioplasty. Eur J Vasc Endovasc Surg 2019;57:578-86.
- Scheinert D, Schmidt A, Zeller T, et al. German center subanalysis of the LEVANT 2 global randomized study of the Lutonix drug-coated balloon in the treatment of femoropopliteal occlusive disease. J Endovasc Ther 2016;23:409-16.
- Kohi MP, Brodmann M, Zeller T, et al. Sex-related differences in the long-term outcomes of patients with femoropopliteal arterial disease treated with the IN.PACT drug-coated balloon in the IN.PACT SFA randomized controlled trial: a post hoc analysis. J Vasc Interv Radiol 2020;31:1410-1418.e10.
- Roh JW, Ko YG, Ahn CM, et al. Risk factors for restenosis after drug-coated balloon angioplasty for complex femoropopliteal arterial occlusive disease. Ann Vasc Surg 2019;55:45-54.